References
- Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP. Protein Kinase Ciota Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell 2016; 29:367-78; PMID:26977885; https://doi.org/10.1016/j.ccell.2016.02.012
- Parker PJ, Justilien V, Riou P, Linch M, Fields AP. Atypical Protein Kinase Ciota as a human oncogene and therapeutic target. Biochem Pharmacol 2014; 88:1-11; PMID:24231509; https://doi.org/10.1016/j.bcp.2013.10.023
- Justilien V, Walsh MP, Ali SA, Thompson EA, Murray NR, Fields AP. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014; 25:139-51; PMID:24525231; https://doi.org/10.1016/j.ccr.2014.01.008
- Justilien V, Fields AP. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene 2009; 28: 3597-607; PMID:19617897; https://doi.org/10.1038/onc.2009.217
- Justilien V, Jameison L, Der CJ, Rossman KL, Fields AP. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J Biol Chem 2011; 286: 8149-57; PMID:21189248; https://doi.org/10.1074/jbc.M110.196113
- Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905-11; PMID:16204062; https://doi.org/10.1158/0008-5472.CAN-05-2372
- Regala RP, Davis RK, Kunz A, Khoor A, Leitges M, Fields AP. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009; 69: 7603-11; PMID:19738040; https://doi.org/10.1158/0008-5472.CAN-09-2066
- Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, Grudem M, Wahner Hendrickson A et al. A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients. Oncology 2014; 88: 208-13; PMID:25502607; https://doi.org/10.1159/000369257
- Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C et al. Phase I dose escalation study of the PKCiota inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013; 24: 1079-83; PMID:23962904; https://doi.org/10.1097/CAD.0000000000000009
- Justilien V, Fields AP. Molecular pathways: novel approaches for improved therapeutic targeting of hedgehog signaling in cancer stem cells. Clin Cancer Res 2015; 21: 505-13; PMID:25646180; https://doi.org/10.1158/1078-0432.CCR-14-0507